Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pro-inflammatory cytokine networks and mediators comprise a diverse group of signaling proteins, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), that orchestrate the immune system's response to injury and infection (StatPearls, 2023: https://www.ncbi.nlm.nih.gov/books/NBK545230/). These molecules are primarily secreted by immune cells like macrophages and lymphocytes, acting to promote inflammation and recruit further immune cells to sites of damage (Nature Reviews Immunology, 2018: https://www.nature.com/articles/nri.2017.125). In a healthy state, these networks are tightly regulated; however, their chronic overproduction is central to the pathogenesis of various inflammatory conditions, including rheumatoid arthritis and Crohn's disease (Frontiers in Immunology, 2021: https://www.frontiersin.org/articles/10.3389/fimmu.2021.650121/full). Pharmacological intervention typically targets specific nodes within these networks, such as using monoclonal antibodies to neutralize TNF-α or IL-6, or small molecule inhibitors to block downstream signaling pathways like the JAK-STAT pathway (Journal of Clinical Investigation, 2017: https://www.jci.org/articles/view/93248). While highly effective in reducing disease activity, modulating these networks carries risks of systemic immunosuppression and increased susceptibility to opportunistic infections (The Lancet, 2019: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30001-9/fulltext).
Drugs targeting these networks function by neutralizing soluble cytokines (e.g., TNF-alpha inhibitors), competitively blocking cytokine receptors (e.g., IL-1 receptor antagonists), or inhibiting intracellular signaling transducers like Janus kinases (JAKs) to prevent the transcription of inflammatory genes (Nature Reviews Drug Discovery, 2022: https://www.nature.com/articles/s41573-021-00356-x).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pro-inflammatory cytokine networks and mediators.